Menu

Gel Heals Heart Attack Injury

A collagen patch seeded with a regenerative protein helps mice and pigs regain cardiac function after a heart attack.

Sep 18, 2015
Kerry Grens

New heart muscle cells (green with yellow nuclei) grow in the infarcted region of a mouse heart treated by the patch loaded with FSTL1.UC SAN DIEGO/SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTETo find a way to repair the damage that happens to cardiac tissue after a heart attack, researchers have developed a patch that delivers a regenerative molecule to the organ’s surface. A team led by Stanford University’s Pilar Ruiz-Lozano reported in Nature yesterday (September 16) that the implant helps restore cardiac function to mice and pigs who have had a heart attack.

“Many were so sick prior to getting the patch that they would have been candidates for heart transplantation,” Ruiz-Lozano told BBC News. “The hope is that a similar procedure could eventually be used in human heart attack patients who suffer severe heart damage.”

The scientists conducted a screen for molecules that could spur the production of cardiomyocytes in vitro, and homed in on a protein, Follistatin-like 1 (FSTL1). They then designed a collagen-based material coated in FSTL1, and placed it on the hearts of pigs and mice forced to have a heart attack.

Within a month, the researchers observed cardiomyocyte division among animals treated with FSTL1, along with improved cardiac function, less scarring, and better survival.

“It could act like a cell nursery,” Ruiz-Lozano said in a press release. “It’s a hospitable environment. Over time, it gets remodeled and becomes vascularized as new muscle cells come in.”

“This study is an inspiring example of how a developmentally conserved regulatory pathway can be mobilized to induce heart regeneration,” Gordana Vunjak-Novakovic of Columbia University wrote in an accompanying commentary. “Although more work needs to be done to determine the benefits of such an approach in large-animal models (the authors conducted a preliminary study in pigs, but it involved only six animals divided into three groups), the proposed reconstitution of epicar­dial Fstl1 could lead to entirely new modalities for treating heart infarction.”

Ruiz-Lozano has a startup company working to develop the patch for clinical trials in humans.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.